Agenus Inc. (AGEN), a clinical-stage immuno-oncology company, on Thursday, announced financial and clinical strategies designed to prioritize its core programs while implementing significant cost-cutting measures.
As part of the strategic realignment, the company has planned to reduce cash burn to $100 million in 2025, following the successful closing of a $22 million mortgage secured by key real estate assets.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com